FAQ : Gynaecological cancer
What are the different types of gynecological cancers?
Gynaecological cancers include all cancers of the female reproductive system: cervix, uterine body (endometrium), ovaries, vulva, vagina, and fallopian tubes.
Information on these cancers can be found in the following questions and answers. For more details, do not hesitate to go to the site Arcagy - InfoCancer.
Ovarian and fallopian tube cancer
What are ovarian and fallopian tube cancers?
Ovarian cancer is a disease where abnormal cells form in the ovaries, which are the female reproductive organs responsible for egg production. Ovarian cancer can develop in various parts of the ovary, including outer surface cells (epithelial cells), egg-producing cells (germ cells), or cells that produce hormones (stromal cells).
Cancer of the fallopian tubes (or uterine tubes) is cancer that is localized in the tubes, which are the thin muscular tubes that connect the ovaries to the uterus. These tubes play a key role in transporting eggs from the ovaries to the uterus for fertilization. Most often, it develops in glandular cells, which are found in the lining of the tubes.
What are the histologies (subtypes) of ovarian cancer?
There are several types of ovarian cancer, which are classified according to the types of cells they come from. The main types include:
Epithelial ovarian cancer : This is the most common type of ovarian cancer, which forms from cells on the outer surface of the ovary. Seven different histological subtypes are distinguished: serous (50 to 70%), endometrioid (10 to 70%), endometrioid (10 to 25%), mucinous (5 to 10%), clear cell (5%) and three much rarer subtypes (with transitional, undifferentiated and mixed cells).
Cancer ofgerm cells of the ovary: This type of cancer develops from the cells that produce eggs.
Stromal tumor : For this type of cancer, the tumor develops from cells that produce the female hormones estrogen and progesterone.
For more information on the different histologies of ovarian cancer, you can consult the site Arcagy - InfoCancer.
What is the TNM score for ovarian cancer?
The TNM score is a classification system used to assess the stage of a cancer, plan treatment, and predict prognosis.
Three parameters must be taken into account:
- The T describes the size and extent of the primary tumor
- The N indicates whether the cancer faces a regional lymph node extension
- The M indicates whether the cancer has spread to other parts of the body, called metastases.
Note that this table is the same for ovarian and tubal cancer.
TNM classification chart for ovarian cancer
Primary tumor (T)
| T | Thickness of the primary tumor |
|---|---|
| Tx | Primary tumor cannot be assessed |
| T0 | No evidence of primary tumor |
| T1 | Tumor limited to the ovaries (one or both) |
| T1a | Tumor limited to a single ovary; capsule intact, no tumor on the surface of the ovary; no malignant cells in ascitic fluid or peritoneal washings |
| T1b | Tumor limited to one or both ovaries; capsules intact, or to the fallopian tubes, no tumor on the surface of the ovary or tubes; no malignant cells in ascitic fluid or peritoneal washings |
| T1c | Tumor limited to one or both ovaries, with either capsular rupture, or tumor on the surface of the ovaries, or malignant cells present in ascitic fluid or peritoneal washings. |
| Tc1 | Intraoperative rupture |
| Tc2 | Preoperative rupture or surface vegetations |
| Tc3 | Malignant cells in ascites or peritoneal washings. |
| T2 | Tumor involving one or both ovaries with pelvic extension |
| T2a | Extension and/or implants to the uterus and/or tubes; no malignant cells in ascitic fluid or peritoneal washings |
| T2b | Extension to other pelvic organs; no malignant cells in ascitic fluid or peritoneal washings |
| T3 | Ovarian tumor with abdominal peritoneal and/or retroperitoneal lymph node extension |
| T3a | Microscopic retroperitoneal metastases ± peritoneum |
| Ta1 | Retroperitoneal lymphadenopathy only (proven by cytology/histology) |
| Ta1 (i) | Adenocarcinomatous focus in the lymph node ≤ 10 mm |
| Ta1 (ii) | Adenocarcinomatous focus in the lymph node > 10 mm |
| Ta2 | Microscopic extrapelvic peritoneal extension ± lymphadenopathy. |
| T3b | Extrapelvic peritoneal metastases ≤ 2 cm ± lymphadenopathy |
| T4 | Distant metastases (excluding peritoneal metastases) |
| IVA | Pleura (positive cytology) |
| IVB | Other metastases including inguinal lymphadenopathy. |
Lymph nodes (N)
| N | Regional lymph node extension |
|---|---|
| Nx | The minimum requirements to classify the regional and/or juxta-regional lymph nodes are not available |
| N0 | No signs of regional lymph node involvement |
| N1 | Signs of regional lymph node involvement |
Distant metastases (M)
| M | Distant metastases |
|---|---|
| Mx | The minimum requirements to assess the presence of distant metastases are not available |
| M0 | No signs of distant metastases |
| M1 | Presence of distant metastases |
What are the biomarkers or genetic mutations involved in ovarian cancer?
Known to increase the risk of breast cancer, mutations in BRCA1 genesAndBRCA2are also associated with an increased risk of ovarian cancer.
What does “sensitive stage” or “resistant stage” mean?
If ovarian cancer recurs within 6 months following initial chemotherapy treatment with Taxol and Carboplatin, it is called a “platinum-resistant” recurrence. This means that treatment with platinum salts has not been effective, and a change in medication will be required to treat the relapse.
If the recurrence occurs after 6 months (or 12 months) after stopping standard treatment, there is a high probability that the treatment will require a combination of chemotherapy agents with platinum salts, as the recurrence is likely to be “platinum sensitive.”
What is chemotherapy for ovarian cancer?
Among the main chemotherapy drugs used to treat this type of cancer, there are mainly associations between a platinum salt And a Taxane. For example, Carboplatin with Paclitaxel (Taxol), which can be administered every three weeks or weekly according to the protocol in place.
Cervical cancer
What is cervical cancer?
This cancer forms in the tissue of the cervix, the lower, narrow part of the uterus. It is usually caused by a persistent infection by certain types of human papillomavirus (HPV), a sexually transmitted infection.
What is the TNM cervical cancer score?
The TNM score is a classification system used to assess the stage of a cancer, plan treatment, and predict prognosis.
Three parameters must be taken into account:
- The T describes the size and extent of the primary tumor
- The N indicates whether the cancer faces a regional lymph node extension
- The M indicates whether the cancer has spread to other parts of the body, called metastases.
TNM classification chart for cervical cancer
Primary tumor (T)
| T | Thickness of the primary tumor |
|---|---|
| Tx | Primary tumor cannot be assessed |
| T0 | No evidence of primary tumor |
| Tis | Carcinoma in situ (pre-invasive carcinoma) |
| T1 | Cervical carcinoma limited to the cervix (disregard cases extending to the uterine body) |
| T1a | Invasive carcinoma diagnosed only by histology. All macroscopically visible lesions (even with superficial invasion) are to be classified as T1b/Stage IB |
| T1a1 | Connective tissue invasion less than 3.0 mm deep and 7.0 mm or less in horizontal spread |
| T1a2 | Connective tissue invasion between 3.0 mm and 5.0 mm with a horizontal spread of 7.0 mm at most |
| T1b | Clinically visible lesion limited to the cervix or microscopic lesions greater than T1a2/IA2 |
| T1b1 | Clinically visible lesion 4.0 cm or less in greatest dimension |
| T1b2 | Clinically visible lesion greater than 4.0 cm in greatest dimension |
| T2 | Tumor extending beyond the cervix but not reaching the pelvic walls or the lower third of the vagina |
| T2a | Without parametrial infiltration |
| T2b | With parametrial infiltration |
| T3 | Tumor extending to the pelvic wall, infiltrating the lower third of the vagina, or causing hydronephrosis or a non-functioning kidney |
| T3a | Tumor involving the lower third of the vagina, without extension to the pelvic wall |
| T3b | Tumor extending to the pelvic wall or presence of hydronephrosis or a non-functioning kidney |
| T4 | Tumor invading the bladder or rectal mucosa or extending beyond the true pelvis |
Lymph nodes (N)
| N | Regional lymph node extension |
|---|---|
| Nx | The minimum requirements to classify the regional and/or juxta-regional lymph nodes are not available |
| N0 | No signs of regional lymph node involvement |
| N1 | Signs of regional lymph node involvement |
Distant metastases (M)
| M | Distant metastases |
|---|---|
| Mx | The minimum requirements to assess the presence of distant metastases are not available |
| M0 | No signs of distant metastases |
| M1 | Presence of distant metastases |
What is the FIGO classification for cervical cancer?
The FIGO (International Federation of Obstetrician Gynecologists) classification was established in 2002 by the WHO and is specific to gynecological cancers. This classification makes it possible to decide on the stage of evolution of the cancer according to the structures affected.
| FIGO stage | Description |
|---|---|
| I | Cancer strictly limited to the cervix |
| IA | Invasive cancer identified only microscopically with stromal invasion: maximum depth of 5 mm |
| IA1 | Depth ≤ 3 mm |
| IA2 | 3 mm < depth ≤ 5 mm |
| IB | Clinical cancer limited to the cervix visible macroscopically or microscopic cancer larger than IA |
| IB1 | T < 2 cm |
| IB2 | 2 ≤ T < 4 cm |
| IB3 | T ≥ 4 cm |
| II | Cancer extending beyond the cervix but not reaching the pelvic wall or the lower third of the vagina |
| IIA | Up to the upper two thirds of the vagina |
| IIA1 | Size T ≤ 4 cm |
| IIA2 | Size T > 4 cm |
| IIB | Parametria (proximal) |
| III | Cancer extending to the pelvic wall and/or the lower third of the vagina (including hydronephrosis) |
| IIIA | Vaginal involvement up to the lower third |
| IIIB | Fixation to the pelvic wall (or hydronephrosis or non-functioning kidney) |
| IIIC1 | Pelvic lymph node involvement |
| IIIC2 | Para-aortic lymph node involvement |
| IV | Cancer extending beyond the true pelvis or to the bladder and/or rectal mucosa |
| IVA | Adjacent organ (bladder, rectum) |
| IVB | Distant |
What are the main treatments used for cervical cancer?
Treatment depends on the stage of the disease. If possible at the localized stage, surgery is proposed.
Another therapeutic option that is often proposed in the context of cervical cancer is chemoradiotherapy. It is a treatment that combines radiation therapy (often external radiation and brachytherapy) and chemotherapy (often cisplatin). Targeted immunotherapy is also used with a treatment such as Keytruda (Pembrolizumab), which is often combined with chemotherapy based on Avastin (Bevacizumab).
Endometrial cancer
What is uterine cancer (or endometrial cancer)?
Uterine cancer is cancer that develops in the lining of the uterus, called the endometrium. Hormonal imbalances, such as excess estrogen without balancing progesterone, are often associated with its development.
What are the main histologies (subtypes) of uterine cancer?
Adenocarcinomas are the most common form of cancer in the uterine body. They develop from the endometrial glands. Sarcomas, on the other hand, are a much rarer form of this type of cancer.
What are the biomarkers or genetic mutations involved in endometrial cancer?
Lynch syndrome : This hereditary cancer predisposition syndrome is caused by mutations in DNA repair genes, such as MLH1, MSH2, MSH6, and PMS2. Women with Lynch syndrome have an increased risk of developing endometrial cancer.
Mutation PIK3CA : This mutation is frequently observed in endometrial cancer. PIK3CA mutations activate the PI3K/Akt/mTOR signaling pathway, which promotes the growth and survival of cancer cells.
Amplification ofHER2 : It has been observed in certain subtypes of endometrial cancer. This genetic alteration can lead to excessive activation of the HER2 signaling pathway, promoting tumor growth.
Knowledge of these mutations can guide the choice of treatments followed and clinical trials in which to participate.
What is the TNM score for endometrial cancer?
The TNM score is a classification system used to assess the stage of a cancer, plan treatment, and predict prognosis.
Three parameters must be taken into account:
- The T describes the size and extent of the primary tumor
- The N indicates whether the cancer faces a regional lymph node extension
- The M indicates whether the cancer has spread to other parts of the body, called metastases.
TNM classification chart for endometrial cancer
Primary tumor (T)
| T | Primary tumor |
|---|---|
| Tx | Primary tumor cannot be assessed |
| T0 | No evidence of primary tumor |
| T1 | Tumor limited to the uterine body |
| T1a | Tumor limited to the endometrium or not exceeding half of the myometrium |
| T1b | Tumor invading half of the myometrium or more than half of the myometrium |
| T2 | Tumor invading the cervical stroma but not extending beyond the uterus |
| T3 | Local and/or regional extension as follows: |
| T3a | Serosa and/or adnexa |
| T3b | Vaginal and/or parametrial involvement |
| T3c | Regional lymph node involvement. N1: pelvic lymph nodes: para-aortic lymph nodes +/- pelvic lymph nodes |
| T4 | Extension to the bladder and/or intestinal mucosa and/or distant metastases |
| IVA | Extension to the bladder and/or intestinal mucosa |
| IVB | Distant metastases including intra-abdominal metastases and/or inguinal lymph nodes |
Lymph nodes (N)
| N | Regional lymph node extension |
|---|---|
| Nx | The minimum requirements to classify the regional and/or juxta-regional lymph nodes are not available |
| N0 | No signs of regional lymph node involvement |
| N1 | Signs of regional lymph node involvement |
Distant metastases (M)
| M | Distant metastases |
|---|---|
| Mx | The minimum requirements to assess the presence of distant metastases are not available |
| M0 | No signs of distant metastases |
| M1 | Presence of distant metastases |
What are the main treatments used for endometrial cancer?
Treatment depends on the stage of the disease. If possible at the localized stage, surgery (hysterectomy) is proposed. In addition, radiation therapy may be implemented. To treat endometrial cancer at more advanced stages or after initial local treatments have failed, chemotherapy is often proposed. And, now, there are also treatment options with immunotherapy, including two new treatments: Jemperli (dostarlimab) and Kysplyx (the combination of pembrolizumab and lenvatinib).
Vaginal cancer
What is vaginal cancer?
Vaginal cancer is a form of cancer that develops in the tissue of the vagina, the muscular canal connecting the uterus to the outside of the body in women. There are several types of vaginal cancer, which are classified according to the types of cells they come from.
What are the histologies (subtypes) of vaginal cancer?
The main types of vaginal cancer include:
Squamous cell carcinoma: It develops from squamous cells in the vaginal mucosa.
Adenocarcinoma: This type of vaginal cancer is formed from glandular cells in the vaginal mucosa.
Small cell carcinoma : It develops from neuroendocrine cells in the vaginal mucosa.
What is the TNM score for vaginal cancer?
The TNM score is a classification system used to assess the stage of a cancer, plan treatment, and predict prognosis.
Three parameters must be taken into account:
- The T describes the size and extent of the primary tumor
- The N indicates whether the cancer faces a regional lymph node extension
- The M indicates whether the cancer has spread to other parts of the body, called metastases.
TNM classification chart for vaginal cancer
Primary tumor (T)
| T | Primary tumor |
|---|---|
| Tx | Primary tumor cannot be assessed |
| T0 | No evidence of primary tumor |
| T1a | The cancer is limited to the vagina and does not exceed 2 cm |
| T1b | The cancer is limited to the vagina and exceeds 2 cm |
| T2a | Submucosal infiltration into the parametrium without involvement of the pelvic wall and does not exceed 2 cm |
| T2b | Submucosal infiltration into the parametrium without involvement of the pelvic wall and exceeding 2 cm |
| T3 | Involvement of the pelvic wall and/or involvement of the lower third of the vagina and/or obstruction of urine flow (hydronephrosis) causing kidney problems |
| T4 | Bladder or rectal involvement or extension outside the pelvis |
Lymph nodes (N)
| N | Regional lymph node extension |
|---|---|
| Nx | The minimum requirements to classify the regional and/or juxta-regional lymph nodes are not available |
| N0 | No signs of regional lymph node involvement |
| N1 | Signs of regional lymph node involvement |
Distant metastases (M)
| M | Distant metastases |
|---|---|
| Mx | Distant metastatic status not assessable |
| M0 | No distant metastases |
| M1 | Presence of distant metastases |
Vulvar cancer
What is vulvar cancer?
This cancer forms in the tissue of the vulva, which is the outer part of the female genitals. The vulva includes the labia majora and minora, the Mount of Venus, the clitoris, and the vaginal vestibule.
What are the histologies (subtypes) of vulvar cancer?
The types of vulvar cancer primarily include:
Squamous cell carcinoma : It is the most common type of vulvar cancer, which is formed from skin cells in the vulva.
Basal cell carcinoma : This type of cancer is formed from basal cells in the skin of the vulva.
Melanoma: Vulvar melanoma develops from pigment-producing cells in the skin.
What is the TNM score for vulvar cancer?
The TNM score is a classification system used to assess the stage of a cancer, plan treatment, and predict prognosis.
Three parameters must be taken into account:
- The T describes the size and extent of the primary tumor
- The N indicates whether the cancer faces a regional lymph node extension
- The M indicates whether the cancer has spread to other parts of the body, called metastases.
TNM classification chart for vulvar cancer
Primary tumor (T)
| T | Primary tumor |
|---|---|
| Tx | Primary tumor cannot be assessed |
| T0 | No evidence of primary tumor |
| T1 | Tumor limited to the vulva or perineum |
| T1a | ≤ 2 cm with stromal invasion ≤ 1 mm |
| T1b | > 2 cm or with stromal invasion > 1 mm |
| T2 | Tumor (of any size) with involvement of the lower urethra and/or the lower third of the vagina or the anus |
| T3 | Tumor invasion of the upper urethra, the upper 2/3 of the vagina, the bladder, the rectal mucosa or the pelvis |
Lymph nodes (N)
| N | Regional lymph node |
|---|---|
| Nx | Lymph node status not assessable |
| N0 | No lymph node metastasis |
| N1a | 1 to 2 lymph nodes, each < 5 mm |
| N1b | 1 lymph node ≥ 5 mm |
| N2a | ≥ 3 metastatic lymph nodes, each ≤ 5 mm |
| N2b | ≥ 2 metastatic lymph nodes ≥ 5 mm |
| N2c | Metastatic lymph nodes with extracapsular extension |
| N3 | Metastatic lymph nodes, fixed or ulcerated |
Distant metastases (M)
| M | Distant metastases |
|---|---|
| Mx | Distant metastatic status not assessable |
| M0 | No distant metastases |
| M1 | Presence of distant metastases |
What are the main treatments used for vulvar cancer?
If possible, the treatment is mostly surgical, but radiation therapy (external and brachytherapy) and chemotherapy (platinum + 5-FU) have been gradually integrated into the treatment protocols.